$3.01
+0.08
(+2.73%)▲
In the last 1 year, Seagen Inc has given 43.0% return, outperforming this stock by 105.7%
In the last 3 years, Moderna Inc has given 23.4% return, outperforming this stock by 119.8%
3.99%
Downside
Day's Volatility :5.25%
Upside
1.31%
51.5%
Downside
52 Weeks Volatility :92.11%
Upside
83.73%
Period | Unity Biotechnology, Inc. | Russel 2000 | Index (Russel 2000) |
---|---|---|---|
3 Months | -34.44% | -6.7% | -6.7% |
6 Months | 7.27% | -6.2% | -6.2% |
1 Year | -62.66% | -5.1% | -5.1% |
3 Years | -96.86% | 26.9% | 26.9% |
Market Capitalization | 41.9M |
Book Value | $4.08 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -4.22 |
Wall Street Target Price | 7.4 |
Profit Margin | 0.0% |
Operating Margin TTM | -20363.56% |
Return On Assets TTM | -26.5% |
Return On Equity TTM | -94.91% |
Revenue TTM | 236.0K |
Revenue Per Share TTM | 0.02 |
Quarterly Revenue Growth YOY | -100.0% |
Gross Profit TTM | -35.2M |
EBITDA | -46.2M |
Diluted Eps TTM | -4.22 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -3.8 |
EPS Estimate Next Year | -3.55 |
EPS Estimate Current Quarter | -1.08 |
EPS Estimate Next Quarter | -1.12 |
What analysts predicted
Upside of 145.85%
Sell
Neutral
Buy
Unity Biotechnology, Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Unity Biotechnology, Inc. | 34.09% | 7.27% | -62.66% | -96.86% | -98.02% |
![]() Moderna, Inc. | -3.38% | -26.73% | -11.31% | 107.29% | 592.96% |
![]() Regeneron Pharmaceuticals, Inc. | -9.68% | -3.07% | 9.61% | 21.54% | 142.61% |
![]() Seagen, Inc. | -2.59% | 59.82% | 42.99% | 22.0% | 220.73% |
![]() Vertex Pharmaceuticals Incorporated | -5.71% | 2.81% | 21.09% | 13.49% | 111.23% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Unity Biotechnology, Inc. | NA | NA | NA | -3.8 | -0.95 | -0.26 | 0.0 | 4.08 |
![]() Moderna, Inc. | 11.22 | 11.22 | 0.0 | -1.9 | 0.27 | 0.12 | 0.0 | 49.12 |
![]() Regeneron Pharmaceuticals, Inc. | 19.72 | 19.72 | 9.01 | 41.59 | 0.19 | 0.1 | 0.0 | 219.38 |
![]() Seagen, Inc. | NA | NA | 18.53 | -2.88 | -0.23 | -0.12 | 0.0 | 14.54 |
![]() Vertex Pharmaceuticals Incorporated | 26.53 | 26.53 | 0.41 | 13.64 | 0.26 | 0.17 | 0.0 | 56.05 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Unity Biotechnology, Inc. | Buy | $41.9M | -98.02% | NA | 0.0% |
![]() Moderna, Inc. | Buy | $48.1B | 592.96% | 11.22 | 31.77% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $79.5B | 142.61% | 19.72 | 33.81% |
![]() Seagen, Inc. | Hold | $36.3B | 220.73% | NA | -31.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $85.0B | 111.23% | 26.53 | 35.4% |
ARCH VENTURE CORP
FMR Inc
Vanguard Group Inc
UBS O'Connor LLC
Mayo Clinic
Acadian Asset Management LLC
Unity Biotechnology, Inc.’s price-to-earnings ratio stands at None
Read MoreUNITY is developing a new class of therapeutics to slow, halt or reverse diseases of aging. UNITY's current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases.
Organization | Unity Biotechnology, Inc. |
Employees | 31 |
CEO | Dr. Anirvan Ghosh Ph.D. |
Industry | Health Technology |
Pennant Park Investment Corp
$5.52
-0.18%
iShares Trust - iShares Investment Grade Corporate Bond BuyWrite Strategy ETF
$33.71
+0.26%
LEMONADE INC
$17.62
+0.51%
INNOVATOR S&P 500 POWER BUFF
$29.83
-0.37%
Remark Holdings, Inc.
$1.21
-9.02%
FIDELITY D&D BANCORP INC
$37.80
-2.11%
IQ MacKay Municipal Intermediate ETF
$24.26
+0.25%
FT CBOE VEST US EQUITY DEEP
$34.72
-0.46%
FIRST TRUST EUROPE
$33.28
-1.26%